

LECTURE SERIES & WORKSHOPS

# CANCER RESEARCH

# 15

**JUNE 2017**

Thursday

**LECTURE**  
📍 **CHL Strassen**  
Amphitheatre

**11.00 - 12.00 pm**

**MEET & EAT \***  
light lunch provided  
**BAM**  
Room Mc Clintock

**12.30 - 14.00 pm**



\*Please register sending a mail to  
[florence.henry@lih.lu](mailto:florence.henry@lih.lu)



**SPEAKER**

**Michel MITTELBRONN**

Head of the Department of Anatomic and Molecular Pathology, Head of Luxembourg Centre of Neuropathology (LCNP) & (FNR) PEARL Chair, Dudelange, Luxembourg

**HOST:**

Department of Oncology

**RESPONSIBLE LIH SCIENTIST:**

Simone Niclou

([simone.niclou@lih.lu](mailto:simone.niclou@lih.lu))

## A STITCH IN TIME SAVES NINE - WHAT ABOUT BRAIN TUMORS?

### ABSTRACT

Until recently, the search for underlying causes for the development of brain tumors was mainly focused on genetic alterations. However, it currently becomes more and more evident that many of the mutations that have been found in brain tumors are neither tumor-type specific, nor drugable but rather facilitate proliferative activity. With the pioneering methylation analysis of the O6-methylguanine-DNA-methyltransferase (MGMT) gene, a first association of epigenetic marks with outcome and prediction for sensitivity to alkylating agents in glioblastoma patients could be demonstrated. Most recently, an even

stronger link between tumor morphology, protein expression profiles and patient prognosis with the epigenetic profile of brain tumors has been established. This epigenetic profiling currently challenges the gold-standard of histological typing and grading of brain tumors since epigenome-wide methylation profiling become a fast and very robust method in neuropathological diagnostics. The epigenetic signatures of brain tumors may provide further insights into the understanding why distinct brain tumors display a characteristic morphology and growth behaviour.

[www.lih.lu](http://www.lih.lu)

Supported by: